Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tissue Scaffolds | 4 | 2022 | 221 | 2.160 |
Why?
|
| Tissue Engineering | 5 | 2022 | 439 | 1.950 |
Why?
|
| Fibroblasts | 3 | 2020 | 1039 | 0.920 |
Why?
|
| Ankle Brachial Index | 1 | 2024 | 41 | 0.810 |
Why?
|
| Bioreactors | 3 | 2020 | 50 | 0.800 |
Why?
|
| Blood Vessel Prosthesis | 3 | 2020 | 141 | 0.780 |
Why?
|
| Intermittent Claudication | 2 | 2024 | 122 | 0.760 |
Why?
|
| Ischemia | 3 | 2024 | 424 | 0.750 |
Why?
|
| Veterans Health | 1 | 2024 | 191 | 0.720 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2022 | 105 | 0.670 |
Why?
|
| Polyethylene Glycols | 3 | 2022 | 649 | 0.640 |
Why?
|
| Vascular Surgical Procedures | 1 | 2024 | 347 | 0.640 |
Why?
|
| Endovascular Procedures | 2 | 2024 | 395 | 0.590 |
Why?
|
| Biodegradable Plastics | 1 | 2019 | 3 | 0.590 |
Why?
|
| Biocompatible Materials | 2 | 2020 | 432 | 0.590 |
Why?
|
| Frailty | 1 | 2022 | 206 | 0.560 |
Why?
|
| Peripheral Arterial Disease | 2 | 2024 | 510 | 0.520 |
Why?
|
| Materials Testing | 1 | 2019 | 346 | 0.520 |
Why?
|
| Venous Thromboembolism | 1 | 2021 | 330 | 0.510 |
Why?
|
| Surgeons | 1 | 2021 | 342 | 0.500 |
Why?
|
| Lower Extremity | 4 | 2022 | 452 | 0.480 |
Why?
|
| Porosity | 3 | 2022 | 95 | 0.470 |
Why?
|
| Polyglycolic Acid | 3 | 2020 | 44 | 0.460 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2020 | 274 | 0.430 |
Why?
|
| Arteries | 3 | 2014 | 262 | 0.390 |
Why?
|
| Risk Assessment | 4 | 2024 | 3784 | 0.360 |
Why?
|
| Aorta, Abdominal | 1 | 2011 | 52 | 0.340 |
Why?
|
| Regenerative Medicine | 1 | 2011 | 49 | 0.330 |
Why?
|
| Extracellular Matrix | 3 | 2022 | 566 | 0.310 |
Why?
|
| Stress, Mechanical | 3 | 2020 | 494 | 0.300 |
Why?
|
| Veterans | 1 | 2021 | 1675 | 0.290 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2011 | 229 | 0.280 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2011 | 450 | 0.280 |
Why?
|
| Risk Factors | 5 | 2024 | 11017 | 0.280 |
Why?
|
| Postoperative Complications | 3 | 2022 | 3022 | 0.210 |
Why?
|
| Treatment Outcome | 4 | 2024 | 11947 | 0.200 |
Why?
|
| Retrospective Studies | 4 | 2024 | 17560 | 0.200 |
Why?
|
| Limb Salvage | 1 | 2024 | 75 | 0.200 |
Why?
|
| Pressure | 3 | 2020 | 228 | 0.180 |
Why?
|
| Frail Elderly | 1 | 2022 | 136 | 0.170 |
Why?
|
| Biomimetics | 1 | 2020 | 41 | 0.160 |
Why?
|
| Tensile Strength | 1 | 2020 | 98 | 0.150 |
Why?
|
| Elastic Modulus | 1 | 2020 | 121 | 0.150 |
Why?
|
| Time Factors | 4 | 2024 | 7173 | 0.150 |
Why?
|
| Cross-Linking Reagents | 1 | 2020 | 207 | 0.150 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 2133 | 0.140 |
Why?
|
| Humans | 13 | 2024 | 147293 | 0.130 |
Why?
|
| Collagen | 1 | 2020 | 460 | 0.130 |
Why?
|
| Extremities | 1 | 2017 | 144 | 0.120 |
Why?
|
| Disease Progression | 1 | 2024 | 2890 | 0.120 |
Why?
|
| Pain | 1 | 2021 | 794 | 0.120 |
Why?
|
| Skin | 1 | 2020 | 759 | 0.110 |
Why?
|
| Receptor, EphB4 | 1 | 2014 | 33 | 0.100 |
Why?
|
| Shear Strength | 1 | 2014 | 73 | 0.100 |
Why?
|
| Saphenous Vein | 1 | 2014 | 37 | 0.100 |
Why?
|
| Aged | 3 | 2024 | 26514 | 0.100 |
Why?
|
| Cell Line | 1 | 2019 | 2832 | 0.100 |
Why?
|
| Hypertonic Solutions | 1 | 2011 | 7 | 0.090 |
Why?
|
| Rats, Nude | 1 | 2011 | 25 | 0.090 |
Why?
|
| Hydrostatic Pressure | 1 | 2011 | 30 | 0.090 |
Why?
|
| Detergents | 1 | 2011 | 43 | 0.090 |
Why?
|
| Patient Readmission | 1 | 2017 | 777 | 0.090 |
Why?
|
| Vascular Patency | 1 | 2011 | 122 | 0.080 |
Why?
|
| X-Ray Microtomography | 1 | 2011 | 114 | 0.080 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 156 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 8430 | 0.080 |
Why?
|
| Length of Stay | 1 | 2017 | 1371 | 0.080 |
Why?
|
| Prosthesis Failure | 1 | 2011 | 127 | 0.080 |
Why?
|
| Suture Techniques | 1 | 2011 | 138 | 0.080 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2011 | 156 | 0.080 |
Why?
|
| Carotid Arteries | 1 | 2011 | 208 | 0.080 |
Why?
|
| Perfusion | 1 | 2011 | 252 | 0.080 |
Why?
|
| Sirolimus | 1 | 2011 | 283 | 0.070 |
Why?
|
| Blood Coagulation | 1 | 2011 | 274 | 0.070 |
Why?
|
| Endothelial Cells | 2 | 2014 | 886 | 0.070 |
Why?
|
| Swine | 1 | 2011 | 828 | 0.070 |
Why?
|
| Biomechanical Phenomena | 1 | 2011 | 873 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2011 | 795 | 0.060 |
Why?
|
| Stem Cells | 1 | 2011 | 630 | 0.060 |
Why?
|
| Cells, Cultured | 2 | 2011 | 4169 | 0.060 |
Why?
|
| United States | 1 | 2021 | 16313 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2011 | 2529 | 0.050 |
Why?
|
| Blood Circulation | 1 | 2002 | 44 | 0.050 |
Why?
|
| Rats | 1 | 2011 | 5613 | 0.050 |
Why?
|
| Pyranocoumarins | 1 | 2002 | 1 | 0.040 |
Why?
|
| Female | 3 | 2024 | 80076 | 0.040 |
Why?
|
| Coumarins | 1 | 2002 | 16 | 0.040 |
Why?
|
| Measles virus | 1 | 2002 | 21 | 0.040 |
Why?
|
| Models, Cardiovascular | 1 | 2002 | 196 | 0.040 |
Why?
|
| Middle Aged | 1 | 2024 | 36821 | 0.040 |
Why?
|
| Vascular Resistance | 1 | 2002 | 372 | 0.040 |
Why?
|
| Animals | 3 | 2011 | 38410 | 0.040 |
Why?
|
| Male | 3 | 2024 | 73950 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2011 | 5272 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2002 | 776 | 0.030 |
Why?
|
| Tissue Survival | 1 | 2014 | 16 | 0.030 |
Why?
|
| Hemorheology | 1 | 2014 | 24 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 365 | 0.020 |
Why?
|
| Postphlebitic Syndrome | 1 | 1989 | 3 | 0.020 |
Why?
|
| Models, Biological | 1 | 2014 | 1772 | 0.020 |
Why?
|
| Apoptosis | 1 | 2014 | 2454 | 0.010 |
Why?
|
| Rheology | 1 | 2002 | 94 | 0.010 |
Why?
|
| Neutral Red | 1 | 2002 | 1 | 0.010 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2002 | 17 | 0.010 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2002 | 91 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2002 | 90 | 0.010 |
Why?
|
| Ribavirin | 1 | 2002 | 81 | 0.010 |
Why?
|
| Virion | 1 | 2002 | 109 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2002 | 355 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2002 | 567 | 0.010 |
Why?
|
| Virus Replication | 1 | 2002 | 521 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2002 | 1127 | 0.010 |
Why?
|
| Adult | 2 | 2014 | 41405 | 0.010 |
Why?
|
| Phlebography | 1 | 1989 | 41 | 0.000 |
Why?
|
| Leg | 1 | 1989 | 243 | 0.000 |
Why?
|
| Prognosis | 1 | 1989 | 4383 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1989 | 8164 | 0.000 |
Why?
|